An α-glucosidase inhibitor, acarbose treatment decreases serum levels of glyceraldehyde-derived advanced glycation end products (AGEs) in patients with type 2 diabetes

Diabetes is a major risk factor for cardiovascular disease (CVD) morbidity and mortality, and the incidence of CVD is 2–4 times greater in diabetic patients than in a general population [1]. There is a growing body of evidence that postprandial hyperglycemia plays an important role in the development and progression of CVD [2, 3]. Indeed, the DECODE study revealed that 2-h postload hyperglycemia was associated with an increased risk of mortality...